development status

        

Drug for Chronic Myeloid Leukemia (Effect on Cancer Stem Cells)



A major problem in treating cancer is that once treated, the cancer "recurs.“ We are developing new treatments to prevent the recurrence of cancer and are working on chronic myelogenous leukemia, a blood cancer.



■ Why cancer recurs (medical issues and needs).

Cancer cells grow from cells that are the source of cancer, i.e.; stem cells. Because cancer stem cells are protected in an environment called a cancer niche, conventional treatment with anticancer drugs cannot attack cancer stem cells while they can attack cancer cells. As long as the cancer stem cells remain, they grow into cancer cells and the disease recurs.



■ Drugs under development (treatment ideas and concepts)

RS5614, a PAI-1 inhibitor, which we are currently developing, will drive cancer stem cells out of the cancer niche, allowing them to be attacked by anticancer drugs. Destroying cancer stem cells prevents cancer recurrence.



We are conducting a phase 2b study (investigators initiated clinical trial) to confirm the therapeutic effects and side effects of RS5614 in patients with chronic myelogenous leukemia, one of the blood cancers, in Tohoku University, Tokai University, and Akita University.